A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

BACKGROUND: This trial explores SM‐88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) METHODS: Forty‐nine patients were randomized to daily 460 or 920 mg oral SM‐88 with MPS (SM‐88 Regimen). The primary endpoint was objective re...

Descripción completa

Detalles Bibliográficos
Autores principales: Noel, Marcus S., Kim, Semmie, Hartley, Marion L., Wong, Steve, Picozzi, Vincent J., Staszewski, Harry, Kim, Dae Won, Van Tornout, Jan M., Philip, Philip Agop, Chung, Vincent, Ocean, Allyson J., Wang‐Gillam, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678093/
https://www.ncbi.nlm.nih.gov/pubmed/35499204
http://dx.doi.org/10.1002/cam4.4768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678093/
https://www.ncbi.nlm.nih.gov/pubmed/35499204
http://dx.doi.org/10.1002/cam4.4768

Ejemplares similares